Featured Research

from universities, journals, and other organizations

New drug to help common bowel disease

Date:
October 29, 2013
Source:
University of Adelaide
Summary:
An international team has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation, based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

Published in the journal Gastroenterology, the study describes the pain mechanism of action for Linaclotide, a recently approved drug for the treatment of chronic abdominal pain and constipation in adult IBS-C patients.

IBS is a potentially debilitating condition with abdominal pain, bloating, diarrhea and/or constipation. It affects up to 15% of western populations, costing millions of dollars annually in Australia alone in lost productivity and health care. Approximately one third of IBS patients are diagnosed as having IBS-C.

"This is a significant finding and very good news for IBS-C sufferers," says study leader Dr Stuart Brierley, NHMRC RD Wright Biomedical Fellow in the University's Nerve-Gut Research Laboratory. "IBS affects many people, particularly women, on a daily basis and has a significant impact on their quality of life. Abdominal pain is often the most troubling symptom to IBS patients and has been the most difficult symptom to treat.

"The drug is effective in relieving abdominal pain associated with IBS-C and is already available and registered for use by IBS-C patients in the USA and Europe. It is yet to go through the regulatory process in Australia."

The research is a collaboration between the Nerve-Gut Research Laboratory, (University of Adelaide) and Ironwood Pharmaceuticals Inc, the developers of Linaclotide. Linaclotide is a new class of medicine and is the only treatment for IBS-C currently registered with the European Medicines Agency; it is also the first prescription treatment available in over six years for adults with IBS-C in the US.

Linaclotide binds the receptor domain of guanylate cyclase-C on the inner lining of the intestines. It is marketed by Ironwood and Forest Laboratories Inc as Linzess® in the US and by Ironwood and Almirall SA as Constella® in Europe. Ironwood has partnerships through which it is conducting clinical trials of Linaclotide in China and Japan. Ironwood is exploring partnership opportunities for advancing Linaclotide in unpartnered territories, including Australia and New Zealand.

Dr Brierley, in the Nerve-Gut Research Laboratory, collaborated with Ironwood to further investigate how Linaclotide acts within the gastrointestinal tract to reduce abdominal pain. It had been shown to increase the secretion of fluids into the intestine and improve transit through the gastrointestinal tract. However, initial trials had shown that it also reduced abdominal pain associated with IBS-C, independently of its action on improving constipation.

Pre-clinical studies by the Nerve-Gut Research Laboratory showed that Linaclotide inhibits pain nerve endings in the intestine through a novel physiological pathway localised to the gastrointestinal tract. "The study also showed the analgesic effect translated into clinical findings in humans," says Dr Brierley. "IBS-C patients given the drug orally showed significant improvement in abdominal pain over those given placebo during a 26-week trial."


Story Source:

The above story is based on materials provided by University of Adelaide. Note: Materials may be edited for content and length.


Journal Reference:

  1. Joel Castro, Andrea M. Harrington, Patrick A. Hughes, Christopher M. Martin, Pei Ge, Courtney M. Shea, Hong Jin, Sarah Jacobson, Gerhard Hannig, Elizabeth Mann, Mitchell B. Cohen, James E. Macdougall, Bernard J. Lavins, Caroline B. Kurtz, Inmaculada Silos-Santiago, Jeffrey M. Johnston, Mark G. Currie, L. Ashley Blackshaw, Stuart M. Brierley. Linaclotide Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and Extracellular Cyclic Guanosine 3′,5′-Monophosphate. Gastroenterology, 2013; DOI: 10.1053/j.gastro.2013.08.017

Cite This Page:

University of Adelaide. "New drug to help common bowel disease." ScienceDaily. ScienceDaily, 29 October 2013. <www.sciencedaily.com/releases/2013/10/131029092047.htm>.
University of Adelaide. (2013, October 29). New drug to help common bowel disease. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2013/10/131029092047.htm
University of Adelaide. "New drug to help common bowel disease." ScienceDaily. www.sciencedaily.com/releases/2013/10/131029092047.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) — An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) — Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) — Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) — It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins